Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 93 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Rejection Clear all
Completed No phase listed Observational

Alveoscopy, Endoscopic Confocal Microscopy and Lung Rejection, Parenchymal Lung Diseases in Vivo

NCT01033201
View directory record Official record
Conditions
Lung Transplant
Interventions
Confocal imaging
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 22, 2026, 8:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection

NCT03575910
View directory record Official record
Conditions
Heart Transplant Failure and Rejection, Heart Failure, Heart Diseases, Heart Failure，Congestive, Transplant; Failure, Heart, Transplant Failure
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
19 Years and older
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 22, 2026, 8:06 AM EDT
Withdrawn No phase listed Observational

Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study

NCT00572286
View directory record Official record
Conditions
Advanced Heart Failure, Heart Transplantation
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2009 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

NCT00483756
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
37
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 22, 2026, 8:06 AM EDT
Terminated Phase 3 Interventional Results available

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

NCT02547220
View directory record Official record
Conditions
Acute Antibody-Mediated Rejection (AMR)
Interventions
Cinryze®, Placebo
Biological · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

NCT00089947
View directory record Official record
Conditions
Renal Transplantation, Graft Rejection
Interventions
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 22, 2026, 8:06 AM EDT
Terminated No phase listed Observational

Personalization of Immunosuppressive Treatment for Organ Transplant Recipients

NCT05747053
View directory record Official record
Conditions
Kidney Injury, Kidney Failure, Kidney Failure, Chronic, Kidney Failure, Acute, Kidney Diseases, Kidney Transplant Rejection, Kidney Transplant Infection, Kidney Transplant; Complications, Kidney Disease, Chronic, Kidney Ischemia
Interventions
AlloSure, PAXGene
Diagnostic Test
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 22, 2026, 8:06 AM EDT
Terminated No phase listed Observational

PET Assessment of Acute Lung Transplant Rejection

NCT02204202
View directory record Official record
Conditions
Lung Disease
Interventions
[18F]FDG, [18F]ISO-1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Not applicable Interventional

Cryoprobe Transbronchial Lung Biopsy in Lung Transplant Patients

NCT01694615
View directory record Official record
Conditions
Lung Transplantation
Interventions
Cryoprobe biopsy, Forceps Biopsy
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

NCT00363116
View directory record Official record
Conditions
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Interventions
Daclizumab
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
23
States / cities
Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 22, 2026, 8:06 AM EDT
Active, not recruiting No phase listed Observational

Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation

NCT04414111
View directory record Official record
Conditions
DGF, Kidney Transplant; Complications
Interventions
Highly suppressive Treg measurement
Diagnostic Test
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
San Bernardino, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Not applicable Interventional Results available

The Effect of Rituximab on the Development of Anti-Donor Antibodies

NCT00695097
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Rituximab, No Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 22, 2026, 8:06 AM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

NCT01644903
View directory record Official record
Conditions
Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 8:06 AM EDT
Terminated Phase 4 Interventional

The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient

NCT01424345
View directory record Official record
Conditions
Kidney Transplant Immunosuppression
Interventions
adjustment of immunosuppressant dosages, adjustment of the dosages of immunosuppressants
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 8:06 AM EDT
Terminated Phase 2 Interventional Results available

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

NCT01399593
View directory record Official record
Conditions
Antibody Mediated Rejection
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 22, 2026, 8:06 AM EDT
Completed No phase listed Observational

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

NCT07415876
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Retrospective Cohort Enrollment, Prospective Cohort Enrollment
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 8:06 AM EDT
Not listed Phase 1Phase 2 Interventional

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

NCT01154387
View directory record Official record
Conditions
End Stage Renal Disease, Renal Transplant
Interventions
Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Tolera Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 22, 2026, 8:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?

NCT00340951
View directory record Official record
Conditions
Lung Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Durham, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Regimen Optimization Study

NCT02137239
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Thymoglobulin, Belatacept, mycophenolate mofetil(MMF), Corticosteroids, Everolimus(EVL), Tacrolimus(TAC)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 3 Interventional

Freedom Study: Myfortic in Kidney Transplant Patients

NCT00101738
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Myfortic
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
9
States / cities
San Francisco, California • Tampa, Florida • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2011 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Phase 4 Interventional Results available

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

NCT00118742
View directory record Official record
Conditions
Liver Transplantation
Interventions
mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine, Sirolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 22, 2026, 8:06 AM EDT
Completed No phase listed Observational

Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients

NCT01289717
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 8:06 AM EDT
Completed Not applicable Interventional Results available

SRL (Sirolimus) Withdrawal

NCT02062944
View directory record Official record
Conditions
Acute Rejection of Liver Transplant, Effects of Immunosuppressant Therapy
Interventions
Sirolimus
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 22, 2026, 8:06 AM EDT